Ratings Decibel Cannabis Company Inc. OTC Markets

Equities

Market Closed - OTC Markets Other stock markets 15:49:56 2024-06-07 EDT			5-day change	1st Jan Change
0.0478 ^USD	-1.44%		-8.25%	-51.42%

05-29	Decibel Cannabis Company Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-29	Decibel Cannabis Company Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Its low valuation, with P/E ratio at 3.25 and 1.86 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
The company shows low valuation levels, with an enterprise value at 0.63 times its sales.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
DECIBEL CANNABIS COMPANY INC.	-51.42%	19.42M		-
DONG-E-E-JIAO CO.,LTD.	+41.50%	6.2B		B-
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-22.89%	4.09B		C+
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+9.36%	3.48B		C
TASLY PHARMACEUTICAL GROUP CO., LTD	-19.39%	2.82B		B-
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-11.05%	2.28B	-	D+
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+45.24%	1.94B		-
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+46.81%	1.53B		-
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-7.51%	1.51B	-	-
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-18.04%	1.47B	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality